Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.78 HKD | -0.17% | -2.69% | +12.67% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Its low valuation, with P/E ratio at 7.89 and 7.01 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.24 for the 2024 fiscal year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.67% | 4.65B | B | ||
+42.60% | 739B | C+ | ||
+32.34% | 598B | B | ||
-5.74% | 353B | C+ | ||
+17.79% | 318B | B- | ||
+3.37% | 285B | C+ | ||
+16.47% | 240B | B+ | ||
+9.26% | 210B | B- | ||
-5.07% | 206B | A+ | ||
+6.74% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 3320 Stock
- Ratings China Resources Pharmaceutical Group Limited